Lin Shen
机构: Peking University Cancer Hospital & Institute
每年引用次数
引用次数
引用: 38,659
H-指数: 85
I10-指数 : 383
出版物: 952
Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study.
Tong Xie , Yiqiang Liu , Zhening Zhang , Xiaotian Zhang
Journal of Immunotherapy 43 ( 4) 139 -144
48
2020
P-0042 Preliminary Safety Analysis From PAC-C Study of Capecitabine+Paclitaxel→Capecitabine Maintenance (PX-X) vs Capecitabine+Cisplatin (XP) As First-Line Chemotherapy for Recurrent/Metastatic Gastric Cancer
Lin Shen , Xiaotian Zhang , Zhihao Lu , Bing Hu
Annals of Oncology 23
2012
Phosphoproteomics Enables Molecular Subtyping and Nomination of Kinase Candidates for Individual Patients of Diffuse-Type Gastric Cancer.
Mengsha Tong , Chunyu Yu , Jinwen Shi , Wenwen Huang
iScience 22 44 -57
4
2019
Determination of a novel photosensitizer sinoporphyrin sodium in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry.
Jun Zhou , Fen Yang , Jia jia Yuan , Yun hai Bo
Journal of Pharmaceutical and Biomedical Analysis 195 113852
2021
Development of an LC-MS/MS method for quantitative analysis of Chlorogenic acid in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor
Fen Yang , Ji fang Gong , Lin Shen , Chen Zhang
Journal of Pharmaceutical and Biomedical Analysis 177 112809 -112809
8
2020
Non‐Gaussian diffusion imaging with a fractional order calculus model to predict response of gastrointestinal stromal tumor to second‐line sunitinib therapy
Lei Tang , Yi Sui , Zheng Zhong , Frederick C. Damen
Magnetic Resonance in Medicine 79 ( 3) 1399 -1406
13
2018
Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer
Rui Liu , Xi Chen , Yiqi Du , Weiyan Yao
Clinical Chemistry 58 ( 3) 610 -618
434
2012
The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Qiwei Wang , Xiaotian Zhang , Enyun Shen , Jing Gao
Cancer Letters 380 ( 1) 20 -30
11
2016
Genomic profiling of early-onset metastatic Chinese colorectal cancer (mCRC) patients: The development of a PFS prediction model for first line treatments.
Xicheng Wang , Lin Shen , Jing Zhang , Lu Zhang
Journal of Clinical Oncology 36 ( 15_suppl) e15657 -e15657
2018
Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).
Whitney Paige Kirschbrown , Bei Wang , Ihsan Nijem , Atsushi Ohtsu
Journal of Clinical Oncology 36 2564 -2564
1
2018
Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).
Ruihua Xu , Jin Li , Yu-Xian Bai , Yanhong Deng
Journal of Clinical Oncology 36 3537 -3537
1
2018
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.
Yu-Xian Bai , Shukui Qin , Jin Li , Yanhong Deng
Journal of Clinical Oncology 36 3544 -3544
1
2018
The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Manish A. Shah , Kohei Shitara , Florian Lordick , Yung-Jue Bang
Journal of Clinical Oncology 36 4010 -4010
11
2018
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
Wenhua Li , Jianming Xu , Lin Shen , Tianshu Liu
BMC Cancer 14 ( 1) 986 -986
4
2014
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first‐line chemotherapy
Furong Kou , Zhihao Lu , Jian Li , Xiaotian Zhang
Cancer Medicine 5 ( 5) 778 -786
32
2016
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Dan Liu , Jian Li , Jing Gao , Yanyan Li
BMC Cancer 17 ( 1) 437 -437
9
2017
Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs
Luohai Chen , Lin Zhou , Meng Zhang , Liang Shang
BMC Cancer 17 ( 1) 1 -11
17
2017
Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
Yan Zhu , Tiantian Tian , Jianling Zou , Qiwei Wang
BMC Cancer 15 ( 1) 894 -894
19
2015
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Jifang Gong , Tianshu Liu , Qingxia Fan , Li Bai
BMC Cancer 16 ( 1) 68 -68
101
2016
Efficacy and safety of weekly nab -paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
Ruihua Xu , Xianjun Yu , Jihui Hao , Liwei Wang
BMC Cancer 17 ( 1) 885 -885
5
2017